tirzepatide and cancer risk Obesity is now responsible for 1 in 10 new diagnoses in the United States every year. For some cancers — endometrial liver in particular — the figure is closer to In a 55-year-old woman with

Wegovys new 7.2mg dose (UK-approved January 2026) also narrows the gap, producing 20.7% average weight loss in its own trial

Maternal selenium deficiency in mice alters placental function, reduces foetal glucose concentrations and impairs foetal growth

"GLP-1/GIP/glucagon receptor tri-agonism: the emerging paradigm in obesity pharmacotherapy." Endocrinology and Metabolism

Get in touch today and lets talk!

Similarly, the STEP UP Obesity trial revealed that about 33% of patients on the 7.2 mg dose lost 25% or more of their starting weight, while only 15% of those on the lower dose achieved the same level of weight loss